CRIM Status and Follow-up of Individuals with Pompe Disease

The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease

S. Banugaria, Sean N. Prater, Y. Ng, et al.. (2011). Genetics in Medicine. Cited 243 times. https://doi.org/10.1097/GIM.0b013e3182174703

Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease

Y. Messinger, N. Mendelsohn, W. Rhead, et al.. (2012). Genetics in Medicine. Cited 206 times. https://doi.org/10.1038/gim.2011.4

The emerging phenotype of long-term survivors with infantile Pompe disease

Sean N. Prater, S. Banugaria, Stephanie M. Dearmey, et al.. (2012). Genetics in Medicine. Cited 184 times. https://doi.org/10.1038/gim.2012.44

Predicting cross‐reactive immunological material (CRIM) status in Pompe disease using GAA mutations: Lessons learned from 10 years of clinical laboratory testing experience

Deeksha S. Bali, J. Goldstein, S. Banugaria, et al.. (2012). American Journal of Medical Genetics Part C: Seminars in Medical Genetics. Cited 126 times. https://doi.org/10.1002/ajmg.c.31319

Algorithm for the Early Diagnosis and Treatment of Patients with Cross Reactive Immunologic Material-Negative Classic Infantile Pompe Disease: A Step towards Improving the Efficacy of ERT

S. Banugaria, Sean N. Prater, Trusha Patel, et al.. (2013). PLoS ONE. Cited 112 times. https://doi.org/10.1371/journal.pone.0067052

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

S. Banugaria, Sean N. Prater, J. McGann, et al.. (2012). Genetics in Medicine. Cited 90 times. https://doi.org/10.1038/gim.2012.110

Persistence of high sustained antibodies to enzyme replacement therapy despite extensive immunomodulatory therapy in an infant with Pompe disease: need for agents to target antibody-secreting plasma cells.

S. Banugaria, Trusha Patel, J. Mackey, et al.. (2012). Molecular genetics and metabolism. Cited 69 times. https://doi.org/10.1016/j.ymgme.2012.01.019

An individually, modified approach to desensitize infants and young children with Pompe disease, and significant reactions to alglucosidase alfa infusions.

A. El-Gharbawy, J. Mackey, Stephanie M. Dearmey, et al.. (2011). Molecular genetics and metabolism. Cited 36 times. https://doi.org/10.1016/j.ymgme.2011.07.004

Atypical immunologic response in a patient with CRIM-negative Pompe disease.

M. Abbott, Sean N. Prater, S. Banugaria, et al.. (2011). Molecular genetics and metabolism. Cited 30 times. https://doi.org/10.1016/j.ymgme.2011.08.003